Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer
Phase II Trial of Cetuximab Plus Cisplatin, 5- Fluorouracil and Radiation in Immunocompetent Patients With Anal Carcinoma
Sponsor: ECOG-ACRIN Cancer Research Group
A PHASE2 clinical study on Anal Cancer, this trial is completed. The trial is conducted by ECOG-ACRIN Cancer Research Group and has accumulated 12 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jul 2022 — Jul 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Jan 2021 — Jul 2022 [monthly]
Active Not Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Feb 2019 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Feb 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adrian, United States, Baltimore, United States, Baton Rouge, United States, Bowling Green, United States, Burnsville, United States, Cedar Rapids, United States, Chanute, United States, Charlottesville, United States, Chicago, United States, Chillicothe, United States and 81 more location s